Lam Research (LRCX) to Post Q3 Earnings: What's in the Cards?
https://www.zacks.com/stock/news/2258614/lam-research-lrcx-to-post-q3-earnings-what-s-in-the-cards?cid=CS-ZC-FT-analyst_blog|earnings_preview-2258614
Apr 19, 2024 - Lam Research's (LRCX) third-quarter fiscal 2024 results are expected to reflect strength in 3D DRAM and advanced packaging amid a slowdown in memory spending.
0
Netflix ETFs to Buy on the Dip Post Solid Q1 Earnings
https://www.zacks.com/stock/news/2258499/netflix-etfs-to-buy-on-the-dip-post-solid-q1-earnings?cid=CS-ZC-FT-etf_news_and_commentary-2258499
Apr 19, 2024 - Netflix (NFLX) topped both earnings and revenue estimates and delivered its strongest first-quarter customer additions since the pandemic. However, it issued disappointing second-quarter revenue guidance, which dragged the stock down.
0
Xerox: Looking To Get Long Post An Encouraging Q1 Report
https://seekingalpha.com/article/4684623-xerox-looking-to-get-long-post-encouraging-q1-earnings?source=feed_all_articles
Apr 18, 2024 - Xerox's profitability rises by over 12%, positive technical trends indicate potential bottoming pattern, and high dividend yield of 6.17%. See more on XRX stock.
0
Danaher (DHR) Gears Up to Post Q1 Earnings: Is a Beat Likely?
https://www.zacks.com/stock/news/2257902/danaher-dhr-gears-up-to-post-q1-earnings-is-a-beat-likely?cid=CS-ZC-FT-analyst_blog|earnings_preview-2257902
Apr 18, 2024 - Danaher's (DHR) Q1 earnings are likely to be hurt by weakness in the Biotechnology unit. Improving supply chains and strong price realization are expected to be positives.
0
NextEra Energy (NEE) to Post Q1 Earnings: What's in Store?
https://www.zacks.com/stock/news/2257828/nextera-energy-nee-to-post-q1-earnings-what-s-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2257828
Apr 18, 2024 - NextEra Energy (NEE) is likely to come out with an earnings surprise this season courtesy of strong performance of its segments and demand from expanding customer base.
0
DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch
https://www.zacks.com/stock/news/2257798/diamedica-dmac-up-as-stroke-study-dosing-begins-post-relaunch?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2257798
Apr 18, 2024 - DiaMedica (DMAC) rises 10% as it doses the first patient in the relaunch of its pivotal study evaluating the lead candidate, DM199, to treat acute ischemic stroke.
0
Bio-Rad Laboratories (BIO) to Post Q1 Earnings: What Awaits?
https://www.zacks.com/stock/news/2257849/bio-rad-laboratories-bio-to-post-q1-earnings-what-awaits?cid=CS-ZC-FT-analyst_blog|earnings_preview-2257849
Apr 18, 2024 - The ongoing weakness in the biopharma end markets and tightening of sanctions against Russia is likely to have hurt Bio-Rad's (BIO) first-quarter 2024 growth.
0
Pages: 12
<Page 2